ViaLase’s chief medical officer, Rick Lewis, discusses the company’s innovative non-incisional glaucoma treatment. The treatment uses advanced imaging technology to create a 500-micron-wide channel in the trabecular meshwork, allowing for precise placement of the channel almost anywhere in the meshwork for 360 degrees. Initial safety studies have shown that the treatment is both safe and effective, with patients experiencing a drop in intraocular pressure without any adverse events.
Moving forward, ViaLase is conducting a pivotal trial with 152 total patients to further evaluate the efficacy and safety of the treatment. The trial compares the femtolaser treatment to an SLT in a randomized manner. Data collection for the 6-month follow-up is expected to be completed next month, with plans to file for FDA approval later this year. The results so far have been promising, showing good safety and efficacy.
The non-incisional approach to treating glaucoma that ViaLase is pioneering has the potential to revolutionize glaucoma treatment. It offers a minimally invasive alternative to traditional incisional surgeries and provides hope for patients struggling with managing their intraocular pressure. With continued research and development, this innovative treatment could become a game-changer in the field of ophthalmology.